Decoy Therapeutics (DCOY) vs Scinai Immunotherapeutics (SCNI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Scinai Immunotherapeutics is the larger company by market cap ($1.6 million vs $995,881), about 1.6 times the size. On valuation, Scinai Immunotherapeutics trades at a lower trailing P/E (0.0x vs 0.1x for Decoy Therapeutics).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DCOY | SCNI |
|---|---|---|
| Share price | $1.52 | $1.21 |
| Market cap | $995.88K | $1.64M |
| 1-day change | -5.59% | +7.08% |
| P/E ratio (TTM) | 0.12 | 0.04 |
| EPS (TTM) | $12.74 | $28.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $55.92 | $15.65 |
| 52-week low | $1.48 | $1.06 |
| Distance from 52-week high | -97.28% | -92.27% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +97.37% | — |
| Average volume | 2.17M | 1.10M |
| Shares outstanding | 655.18K | 1.35M |
| Employees | 11 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Decoy Therapeutics trades at a higher earnings multiple (0.1x vs 0.0x trailing P/E).
About Decoy Therapeutics
DCOY stock →Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company.
Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees
About Scinai Immunotherapeutics
SCNI stock →Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees
DCOY vs SCNI FAQ
Which is bigger, Decoy Therapeutics or Scinai Immunotherapeutics?
Scinai Immunotherapeutics (SCNI) is larger, with a market capitalization of $1.64M compared with $995.88K for Decoy Therapeutics (DCOY).
Which has the lower P/E ratio, DCOY or SCNI?
SCNI has the lower trailing P/E at 0.0, versus 0.1 for DCOY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Decoy Therapeutics and Scinai Immunotherapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Decoy Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Scinai Immunotherapeutics.